Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Theriva Biologics Inc News

    0,4100 0,00% +0,00
    02:00:00 Uhr AMEX aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A3DMG6
    ISIN: US87164U4094
    US-Symbol: TOVX
    Typ: Aktie

    Theriva Biologics Inc News

    25.07.22 - PR Newswire
    Thinking about buying stock in Synthetic Biologics, Revelation Biosciences, Geovax Labs, Chimerix, or Zymergen?
    Thinking about buying stock in Synthetic Biologics, Revelation Biosciences, Geovax Labs, Chimerix, or Zymergen? PR Newswire
    09.02.22 - PR Newswire
    Synthetic Biologics to Present at 2022 BIO CEO & Investor Conference
    Synthetic Biologics to Present at 2022 BIO CEO & Investor Conference PR Newswire
    08.02.22 - PR Newswire
    Synthetic Biologics Announces VCN Biosciences' VCN-01 Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDA
    Synthetic Biologics Announces VCN Biosciences' VCN-01 Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDA Follows recent announcement of planned ...
    26.01.22 - PR Newswire
    Synthetic Biologics to Present at the B. Riley Securities Oncology Conference on January 28, 2022
    Synthetic Biologics to Present at the B. Riley Securities Oncology Conference on January 28, 2022 PR Newswire
    14.12.21 - PR Newswire
    Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors
    Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors ...
    03.11.21 - PR Newswire
    Synthetic Biologics Reports Third Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET
    Synthetic Biologics Reports Third Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET Initiated a Phase 1 Multiple ...
    26.10.21 - PR Newswire
    Synthetic Biologics to Report 2021 Third Quarter Operational Highlights and Financial Results on November 3, 2021
    Synthetic Biologics to Report 2021 Third Quarter Operational Highlights and Financial Results on November 3, 2021 -- Conference Call Scheduled for Wednesday, November 3, ...
    21.10.21 - PR Newswire
    Synthetic Biologics Announces Initiation of a Phase 1 Multiple-Ascending Dose Clinical Trial for SYN-020 Intestinal Alkaline Phosphatase
    Synthetic Biologics Announces Initiation of a Phase 1 Multiple-​Ascending Dose Clinical Trial for SYN-020 Intestinal Alkaline Phosphatase Topline Data Readout Expected in Q2 ...
    06.10.21 - PR Newswire
    Synthetic Biologics Announces Second Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum
    Synthetic Biologics Announces Second Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum The Company Encourages All Shareholders of Record Who Have ...
    21.09.21 - PR Newswire
    Synthetic Biologics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum
    Synthetic Biologics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum PR Newswire
    05.08.21 - PR Newswire
    Synthetic Biologics Reports Second Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET
    Synthetic Biologics Reports Second Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET Phase 1 Single-​Ascending Dose ...
    28.07.21 - PR Newswire
    Synthetic Biologics to Report 2021 Second Quarter Operational Highlights and Financial Results on August 5, 2021
    Synthetic Biologics to Report 2021 Second Quarter Operational Highlights and Financial Results on August 5, 2021 Conference Call Scheduled for Thursday, August 5, 2021 at 4:30 ...
    29.06.21 - PR Newswire
    Synthetic Biologics Provides Update on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Single-Ascending Dose Clinical Trial
    Synthetic Biologics Provides Update on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Single-​Ascending Dose Clinical Trial Orally Administered SYN-020 Observed to be Well ...
    26.05.21 - PR Newswire
    Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards
    Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards PR Newswire
    28.04.21 - PR Newswire
    Synthetic Biologics to Report 2021 First Quarter Operational Highlights and Financial Results on May 5, 2021
    Synthetic Biologics to Report 2021 First Quarter Operational Highlights and Financial Results on May 5, 2021 -- Conference Call Scheduled for Wednesday, May 5, 2021 at 4:30 p.m. ...
    14.04.21 - PR Newswire
    Synthetic Biologics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
    Synthetic Biologics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients PR Newswire
    01.04.21 - PR Newswire
    Synthetic Biologics Announces First Six Participants Dosed in Phase 1a Clinical Trial of SYN-020 Intestinal Alkaline Phosphatase
    Synthetic Biologics Announces First Six Participants Dosed in Phase 1a Clinical Trial of SYN-020 Intestinal Alkaline Phosphatase A Multiple-​Ascending Dose Study is on Track to ...
    04.03.21 - PR Newswire
    Synthetic Biologics Reports 2020 Year End Operational Highlights and Financial Results
    Synthetic Biologics Reports 2020 Year End Operational Highlights and Financial Results -- Announced Washington University Has Begun Screening Patients for Enrollment in ...
    25.02.21 - PR Newswire
    Synthetic Biologics to Report 2020 Year End Operational Highlights and Financial Results on March 4, 2021
    Synthetic Biologics to Report 2020 Year End Operational Highlights and Financial Results on March 4, 2021 -- Conference Call Scheduled for Thursday, March 4, 2021 at 4:30 p.m. ...
    22.12.20 - PR Newswire
    Synthetic Biologics Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol
    Synthetic Biologics Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol IRB Approval Signals ...

    Newssuche

    Videos

    25.04.24 +21,95%
    Technical Trading: S&P 500 Short Chance
    S&P 500 Short Typ: Turbo Open End WKN: NG8FUZ Hebel: 31 Laufzeit: OpenEnd Einstieg: Market ... Mehr »